Literature DB >> 14726621

Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level.

Basil Obeidat1, John Latimer, Robin Crawford.   

Abstract

The aim of this study was to determine the ability of preoperative serum CA-125 levels to predict optimal cytoreduction in patients with stage III epithelial ovarian cancer. A retrospective review was made of the records of 40 patients with FIGO stage III ovarian carcinoma who underwent primary cytoreductive surgery. A receiver operating characteristic (ROC) curve was used to determine the most useful CA-125 level in predicting optimal versus suboptimal tumour cytoreduction. Twenty-two (55%) patients were optimally cytoreduced (residual disease <or=1 cm). A preoperative serum CA-125 level of 500 U/ml was found to be the value with the most predictive power. Optimal cytoreduction was obtained in 16 of the 21 cases (76%) with a CA-125 <500 U/ml compared to only 6 of the 19 cases (32%) with a CA-125 >500 U/ml. At this threshold, preoperative serum CA-125 level was able to predict optimal versus suboptimal cytoreduction with a sensitivity of 72%, specificity of 73%, positive predictive value of 68%, and negative predictive value of 76%. In the management of patients with advanced epithelial ovarian carcinoma, preoperative serum CA-125 level may help to predict optimal primary cytoreduction and to identify candidates for alternative approaches other than traditional primary cytoreductive surgery, such as neoadjuvant chemotherapy. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726621     DOI: 10.1159/000076236

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  14 in total

1.  In reply.

Authors:  Seung-Chul Yoo; Suk-Joon Chang
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

Review 2.  Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls.

Authors:  Iván Díaz-Padilla; Albiruni Ryan Abdul Razak; Lucas Minig; Marcus Q Bernardini; Josep María Del Campo
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

Review 3.  A framework for a personalized surgical approach to ovarian cancer.

Authors:  Alpa M Nick; Robert L Coleman; Pedro T Ramirez; Anil K Sood
Journal:  Nat Rev Clin Oncol       Date:  2015-02-24       Impact factor: 66.675

4.  Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients.

Authors:  Elham Saffarieh; Setare Nassiri; Majid Mirmohammadkhani
Journal:  Eur J Transl Myol       Date:  2022-08-01

5.  A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.

Authors:  Mona Aarenstrup Karlsen; Carsten Fagö-Olsen; Estrid Høgdall; Tine Henrichsen Schnack; Ib Jarle Christensen; Lotte Nedergaard; Lene Lundvall; Magnus Christian Lydolph; Svend Aage Engelholm; Claus Høgdall
Journal:  Tumour Biol       Date:  2016-07-20

Review 6.  Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer.

Authors:  Peter E Schwartz
Journal:  Curr Oncol Rep       Date:  2009-11       Impact factor: 5.075

7.  Evaluation of Computed Tomography Scan and CA 125 Response in Predicting Operability in Advanced Ovarian Cancer and Assessing Survival Outcome in Interval Cytoreductive Surgery.

Authors:  P Rema; Elizabeth Reshmi John; Suchetha Samabasivan; Anil Prahladan; Preethi George; J Siva Ranjith; Shaji Thomas
Journal:  Indian J Surg Oncol       Date:  2019-01-03

Review 8.  The Significance of Normal Pretreatment Levels of CA125 (<35 U/mL) in Epithelial Ovarian Carcinoma.

Authors:  Joseph Menczer; Erez Ben-Shem; Abraham Golan; Tally Levy
Journal:  Rambam Maimonides Med J       Date:  2015-01-29

9.  Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy.

Authors:  Makoto Yamamoto; Tetsuya Tsujikawa; Yuko Fujita; Yoko Chino; Tetsuji Kurokawa; Yasushi Kiyono; Hidehiko Okazawa; Yoshio Yoshida
Journal:  Cancer Sci       Date:  2016-02-23       Impact factor: 6.716

10.  Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer.

Authors:  Aurélie Pelissier; Aurélie Roulot; Béatrice Guéry; Claire Bonneau; Dominique Bellet; Roman Rouzier
Journal:  J Ovarian Res       Date:  2016-09-27       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.